CONFERENCE COVERAGE SERIES
International Conference on Alzheimer's Disease 2008
Chicago, IL, U.S.A.
26 – 31 July 2008
Chicago: Studies Probe Diminishing Placebo Decline, Part 1
In Alzheimer disease clinical trials, placebo groups seem to be worsening at a more leisurely rate than they once did...
Chicago: Studies Probe Diminishing Placebo Decline, Part 2
Are oddly behaving placebo groups scuppering clinical trials, or are potential treatments simply not living up to expectation?...
Chicago: ICAD Offered Mix Bag of Setbacks and Hopeful News
On 31 July, the 11th International Conference on AD drew to a close...
Chicago: Trial Design Bedevils Search for New AD Drugs, Part 1
On the last day of ICAD, recent disappointing AD trial results were put into a broader perspective...
Chicago: The Phase 2 Problem and the Way to a Surrogate, Part 2
Companies have dealt with the uncertainty created by the Phase 2 problem in clinical trial design in several ways...
Chicago: Out of the Blue—A Tau-based Treatment for AD?
Of all clinical trials reported at the ICAD, one targeting the protein tau was the <em>therapy du jour</em>...
Chicago: Dimebon Safe for 18 Months
An oral antihistamine has emerged in the race to become the first AD drug with stronger, more lasting benefit than any of the drugs currently available...
Chicago: Bapineuzumab’s Phase 2—Was the Data Better Than the Spin?
The story of how Elan/Wyeth’s antibody therapy fared at the ICAD is one of the stranger tales in AD drug development...
Chicago: Lilly’s Antibody Appears to Do No Harm, But Will It Help?
It’s instructive to learn how pharmaceutical companies are navigating the transition for new experimental AD drugs from Phase 2 to 3...
Chicago: APP Roles in Caspase Gene Regulation, Muscle Function?
One way to get the lowdown on someone is to check out the person’s closest friends and colleagues...
Chicago: Flurizan Postmortem
At the International Conference for Alzheimer’s Disease, investigators reported results on a range of different clinical trials...
Chicago: Translational and Basic Science of Tau Advances
The International Conference on Alzheimer’s Disease featured some noteworthy preclinical and basic science tau developments...
Chicago: Brain-Penetrant Microtubule Stabilizer in Tauopathy Mice
Another preclinical study presented at the ICAD capitalized on tau’s microtubule-binding property...
Chicago: Tau Projection Domain May Block Excitotoxicity in Mice
The development of tau-based drugs for AD depends on a deeper understanding of how tau begins to run amok in the first place...
Chicago: Does Saying “I Do” Lower Late-life Dementia Risk?
The newest potential protective factor for Alzheimer’s might be wrapped around your ring finger...
Chicago: More News From Phase 2s
At the International Conference for Alzheimer’s Disease, several investigators presented data on compounds in Phase 2...
Chicago: More Phase 2 News—PBT2 and IVIg
Two anti-amyloid approaches—PBT2 and IVIg—came out with Phase 2 data at ICAD...
Chicago: Phase 2 News—Therapeutic Breakfast Food?
While the media focuses on the next potential billion-dollar pharmaceutical treatment of AD, other investigators have been quietly cooking up alternative approaches...